Published in Clin Cancer Res on July 26, 2011
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med (2012) 1.68
Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat Chem Biol (2012) 1.55
Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest (2013) 0.96
Autophagy paradox and ceramide. Biochim Biophys Acta (2013) 0.89
A new microRNA signal pathway regulated by long noncoding RNA TGFB2-OT1 in autophagy and inflammation of vascular endothelial cells. Autophagy (2015) 0.87
Ceramide induced mitophagy and tumor suppression. Biochim Biophys Acta (2015) 0.84
C2-ceramide induces cell death and protective autophagy in head and neck squamous cell carcinoma cells. Int J Mol Sci (2014) 0.82
Ceramide mediates nanovesicle shedding and cell death in response to phosphatidylinositol ether lipid analogs and perifosine. Cell Death Dis (2012) 0.81
Role of Sphingolipids and Metabolizing Enzymes in Hematological Malignancies. Mol Cells (2015) 0.80
The impact of sphingosine kinase-1 in head and neck cancer. Biomolecules (2013) 0.77
Increasing doxorubicin activity against breast cancer cells using PPARγ-ligands and by exploiting circadian rhythms. Br J Pharmacol (2013) 0.76
Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. Blood (2016) 0.76
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin (2011) 30.81
The molecular biology of head and neck cancer. Nat Rev Cancer (2010) 9.84
Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer (2004) 5.63
Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods (2006) 4.31
Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods (2005) 3.42
Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer (2008) 2.98
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2005) 2.83
Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett (2004) 1.88
Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J Biol Chem (2004) 1.84
Ceramide biogenesis is required for radiation-induced apoptosis in the germ line of C. elegans. Science (2008) 1.83
Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways. FASEB J (2009) 1.82
Proper inference from Simon's two-stage designs. Stat Med (2008) 1.75
Protection of C. elegans from anoxia by HYL-2 ceramide synthase. Science (2009) 1.75
Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J Lipid Res (2010) 1.72
Structure-specific, quantitative methods for analysis of sphingolipids by liquid chromatography-tandem mass spectrometry: "inside-out" sphingolipidomics. Methods Enzymol (2007) 1.63
Ceramide synthases 2, 5, and 6 confer distinct roles in radiation-induced apoptosis in HeLa cells. Cell Signal (2010) 1.60
Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol Cancer Ther (2007) 1.55
Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol (2010) 1.53
Subcellular organelle lipidomics in TLR-4-activated macrophages. J Lipid Res (2010) 1.46
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck (2010) 1.45
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res (2010) 1.43
Ceramide synthases: roles in cell physiology and signaling. Adv Exp Med Biol (2010) 1.30
Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs (2010) 1.25
Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res (2008) 1.22
Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery. PLoS One (2010) 1.13
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol (2009) 1.12
Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood (2010) 1.09
A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol (1994) 1.09
A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res (2011) 1.05
Advances and Perspectives in the Molecular Diagnosis of Head and Neck Cancer. Expert Opin Med Diagn (2010) 1.03
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther (2010) 1.03
Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells. Otolaryngol Head Neck Surg (2005) 1.02
Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma Res (2009) 0.92
Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data. Otolaryngol Head Neck Surg (2011) 0.89
The usefulness of new serum tumor markers in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg (2009) 0.83
Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study. Cancer Chemother Pharmacol (2011) 0.80
A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer. Cancer (2010) 0.78
A phase II study of Adriamycin in previously untreated squamous cell carcinoma of the head and neck. Cancer (1985) 0.77
Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA (2008) 13.69
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer (2004) 5.63
Eliminating catheter-related bloodstream infections in the intensive care unit. Crit Care Med (2004) 5.47
Oral cancer and precancerous lesions. CA Cancer J Clin (2002) 4.76
Comparison of "B" readers' interpretations of chest radiographs for asbestos related changes. Acad Radiol (2004) 4.71
Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods (2006) 4.31
The accuracy of surrogate decision makers: a systematic review. Arch Intern Med (2006) 4.17
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Development in infants with autism spectrum disorders: a prospective study. J Child Psychol Psychiatry (2006) 3.54
Social and communication development in toddlers with early and later diagnosis of autism spectrum disorders. Arch Gen Psychiatry (2007) 3.29
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol (2007) 3.23
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide. Nature (2007) 3.13
The complex life of simple sphingolipids. EMBO Rep (2004) 3.10
Upper-airway stimulation for obstructive sleep apnea. N Engl J Med (2014) 2.98
EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res (2004) 2.78
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology (2004) 2.77
Bioactive sphingolipids: metabolism and function. J Lipid Res (2008) 2.73
Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest (2004) 2.73
Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta (2002) 2.69
Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care (2002) 2.51
Preoxygenation is more effective in the 25 degrees head-up position than in the supine position in severely obese patients: a randomized controlled study. Anesthesiology (2005) 2.42
Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes (2010) 2.35
An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol (2010) 2.33
Clinical practice guideline: hoarseness (dysphonia). Otolaryngol Head Neck Surg (2009) 2.31
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol (2013) 2.29
De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J Biol Chem (2002) 2.24
The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal (2007) 2.16
PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane. Extracellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-acetate (PMA). J Biol Chem (2002) 2.11
Extracapsular dissection for benign parotid tumors: a meta-analysis. Laryngoscope (2012) 2.11
The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J (2003) 2.10
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. Clin Cancer Res (2005) 2.10
Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem Cell Biol (2004) 2.06
Cost-efficacy of surgically induced weight loss for the management of type 2 diabetes: a randomized controlled trial. Diabetes Care (2009) 2.04
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03
Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab (2009) 2.00
Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis. Diabetes Care (2009) 2.00
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.93
Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes (2006) 1.91
Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis (2007) 1.91
Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res (2009) 1.85
Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J Biol Chem (2004) 1.84
Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J (2005) 1.83
Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways. FASEB J (2009) 1.82
Depression in association with severe obesity: changes with weight loss. Arch Intern Med (2003) 1.80
Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J (2008) 1.78
Laboratory versus portable sleep studies: a meta-analysis. Laryngoscope (2006) 1.78
Simulation and validation of modelled sphingolipid metabolism in Saccharomyces cerevisiae. Nature (2005) 1.76
Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2. J Biol Chem (2003) 1.76
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
Biochemical properties of mammalian neutral sphingomyelinase 2 and its role in sphingolipid metabolism. J Biol Chem (2003) 1.75
Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J Biol Chem (2002) 1.74
Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J Lipid Res (2010) 1.72
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest (2013) 1.72
A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J (2008) 1.71
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med (2012) 1.68
Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg (2008) 1.68
Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans. J Clin Invest (2003) 1.66
Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med (2013) 1.66
Response to joint attention in toddlers at risk for autism spectrum disorder: a prospective study. J Autism Dev Disord (2007) 1.65
The extended family of neutral sphingomyelinases. Biochemistry (2006) 1.63
Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.62
Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell Signal (2009) 1.62
Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-alpha. J Biol Chem (2005) 1.61
Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem (2007) 1.61
The canalith repositioning procedure for benign positional vertigo: a meta-analysis. Laryngoscope (2004) 1.60
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood (2006) 1.59
Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res (2006) 1.58
Minimal reporting requirements for weight loss: current methods not ideal. Obes Surg (2005) 1.58
Loss of sphingosine kinase-1 activates the intrinsic pathway of programmed cell death: modulation of sphingolipid levels and the induction of apoptosis. FASEB J (2005) 1.57
Prevalence and determinants of physician bedside rationing: data from Europe. J Gen Intern Med (2006) 1.57
Ceramide synthases at the centre of sphingolipid metabolism and biology. Biochem J (2012) 1.57
Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J (2008) 1.56